The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans
- 369 Downloads
In the United States, renal cell carcinoma (RCC) incidence is higher among blacks than among whites. Risk of RCC is elevated among end-stage renal disease patients, although no studies have looked at differences by race in the relationship between chronic renal failure and RCC.
We investigated RCC risk in relation to chronic renal failure in a population-based case–control study of blacks and whites in Chicago and Detroit. Data, including information on kidney disease, were collected from interviews with 1,217 RCC cases (361 blacks, 856 whites) and 1,235 controls (523 blacks, 712 whites). Odds ratios (OR) and 95 % confidence intervals (CI) were estimated using unconditional logistic regression.
Risk of RCC was increased in relation to chronic renal failure (OR 4.7, 95 % CI 2.2–10.1) and dialysis (OR 18.0, 95 % CI 3.6–91). The association remained after defining exposure as those who had chronic renal failure ≥10 years prior to RCC diagnosis. Chronic renal failure was more strongly associated with RCC among blacks than among whites (OR 8.7, 95 % CI 3.3–22.9 and 2.0, 0.7–5.6, respectively; p interaction = 0.03) and among those without a history of diabetes relative to diabetic subjects (OR 8.3, 95 % CI 3.1–22.7 and 1.9, 0.6–5.9, respectively; p interaction = 0.03).
These results suggest that chronic renal failure is a strong risk factor for RCC, particularly among black and non-diabetic subjects. Our findings of differences in risk estimates by race, to our knowledge the first such report, require replication.
KeywordsRenal cell carcinoma Kidney cancer Chronic renal failure End-stage renal disease Racial disparities
This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. The authors thank Faith Davis and other staff in the Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago for their contributions to data collection, as well as Kate Torres, Marsha Dunn, and other staff at Westat, Inc. and Stella Munuo and other staff at Information Management Services, Inc. for their efforts on this project. Finally, the authors express their gratitude to the participants in this study for their involvement.
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14:197–207PubMedCrossRefGoogle Scholar
- 8.United States Renal Data System (2011) USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, BethesdaGoogle Scholar
- 19.Fung MM, Salem RM, Lipkowitz MS, Bhatnagar V, Pandey B, Schork NJ, O’Connor DT (2011) Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American study of kidney disease and hypertension (AASK) trial and veterans affairs hypertension cohort (VAHC). Nephrol Dial Transplant 27:197–205PubMedCrossRefGoogle Scholar
- 20.Heidland A, Bahner U, Vamvakas S (2000) Incidence and spectrum of dialysis-associated cancer in three continents. Am J Kidney Dis 35:347–351; discussion 52–53Google Scholar
- 23.Centers for Disease Control and Prevention (2007) Prevalence of chronic kidney disease and associated risk factors—United States, 1999–2004. MMWR Morb Mortal Wkly Rep 56:161–165Google Scholar